[N-Allyl-Dmt1]-endomorphins are μ-opioid receptor antagonists lacking inverse agonist properties

Journal of Pharmacology and Experimental Therapeutics

Volumn 323, Issue 1, 2007, Pages 374-380

  Marczak, Ewa D ^a   Jinsmaa, Yunden ^b   Li, Tingyou ^c   Bryant, Sharon D ^a   Tsuda, Yuko ^d   Okada, Yoshio ^d   Lazarus, Lawrence H ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c JILIN UNIVERSITY   (China)

^d KOBE GAKUIN UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

(N ALLYL 2',6' DIMETHYLTYROSINE)ENDOMORPHIN 1; (N ALLYL 2',6' DIMETHYLTYROSINE)ENDOMORPHIN 2; ALCOHOL; ALLYL COMPOUND; CYCLIC AMP; ENDORPHIN DERIVATIVE; FORSKOLIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); GUANOSINE 5' O (3 THIOTRIPHOSPHATE) S 35; LOPERAMIDE; MORPHINE; MU OPIATE RECEPTOR ANTAGONIST; NALOXONE; NALTREXONE; UNCLASSIFIED DRUG; 2',6' DIMETHYLTYROSINE; 2',6'-DIMETHYLTYROSINE; DRUG DERIVATIVE; ENDOMORPHIN 1; ENDOMORPHIN 2; MU OPIATE RECEPTOR; NARCOTIC ANALGESIC AGENT; OLIGOPEPTIDE; TYROSINE;

ALCOHOLISM; ALKYLATION; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DEPENDENCE; DRUG MECHANISM; DRUG SELECTIVITY; MALE; MORPHINE ADDICTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SYMPTOMATOLOGY; WITHDRAWAL SYNDROME; ANIMAL; BRAIN; CELL LINE; CHEMISTRY; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; METABOLISM; PROTEIN BINDING; RADIOASSAY;

ANALGESICS, OPIOID; ANIMALS; BRAIN; CELL LINE; CELL MEMBRANE; CYCLIC AMP; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); MALE; MICE; OLIGOPEPTIDES; PROTEIN BINDING; RADIOLIGAND ASSAY; RECEPTORS, OPIOID, MU; SUBSTANCE WITHDRAWAL SYNDROME; TYROSINE;

EID: 34548846698     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.125807     Document Type: Article

References (39)

1. Arunlakshana O and Schild HO (1959) Some quantitative uses of drug antagonists. Br J Pharmacol Chemother 14:48-58.
2. Bardo MT (1998) Neuropharmacological mechanisms of drug reward: beyond dopamine in the nucleus accumbens. Crit Rev Neurobiol 12:37-67.
3. 2 and the protein kinase inhibitors H7 and H8 on acute morphine dependence and antinociceptive tolerance in mice. J Pharmacol Exp Ther 277:484-490.
4. Burford NT, Wang D, and Sadee W (2000) G-Protein coupling of mu-opioid receptors (OP3): elevated basal signalling activity. Biochem J 348:531-537.
5. Chakrabarti S, Rivera M, Yan SZ, Tang WJ, and Gintzler AR (1998) Chronic morphine augments Gβγ/Gsα stimulation of adenylyl cyclase: relevance to opioid tolerance. Mol Pharmacol 54:655-662.
6. Charness ME, Hu G, Edwards RH, and Querimit LA (1993) Ethanol increases delta-opioid receptor gene expression in neuronal cell lines. Mol Pharmacol 44:1119-1127.
7. Charness ME, Querimit LA, and Henteleff M (1988) Ethanol differentially regulates G proteins in neural cells. Biochem Biophys Res Commun 155:138-143.
8. 50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
9. Contet C, Kieffer BL, and Befort K (2004) Mu opioid receptor: a gateway to drug addiction. Curr Opin Neurobiol 14:370-378.
10. Cowen MS and Lawrence AJ (1999) The role of opioid-dopamine interactions in the induction and maintenance of ethanol consumption. Prog Neuropsychopharmacol Biol Psychiatry 23:1171-1212.
11. Cowen MS, Rezvani AH, Jarrott B, and Lawrence AJ (1999) Ethanol consumption by Fawn-Hooded rats following abstinence: effect of naltrexone and changes in mu-opioid receptor density. Alcohol Clin Exp Res 23:1008-1014.
12. Cruz SL, Villarreal JE, and Volkow ND (1996) Further evidence that naloxone acts as an inverse opiate agonist: implications for drug dependence and withdrawal. Life Sci 58:PL381-PL389.
13. Di Chiara G, Acquas E, and Tanda G (1996) Ethanol as a neurochemical surrogate of conventional reinforcers: the dopamine-opioid link. Alcohol 13:13-17.
14. Freye E and Levy J (2005) Constitutive opioid receptor activation: a prerequisite mechanism involved in acute opioid withdrawal. Addict Biol 10:131-137.
15. Gintzler AR and Chakrabarti S (2006) Post-opioid receptor adaptations to chronic morphine; altered functionality and associations of signaling molecules. Life Sci 79:717-722.
16. Gordon AS, Collier K, and Diamond I (1986) Ethanol regulation of adenosine receptor-stimulated cAMP levels in a clonal neural cell line: an in vitro model of cellular tolerance to ethanol. Proc Natl Acad Sci U S A 83:2105-2108.
17. Gordon AS, Wrubel B, Collier K, Estrin W, and Diamond I (1987) Adaptation to ethanol in cultured neural cells and human lymphocytes from alcoholics. Ann N Y Acad Sci 492:367-374.
18. Hall FS, Sora I, and Uhl GR (2001) Ethanol consumption and reward are decreased in mu-opiate receptor knockout mice. Psychopharmacology (Berl) 154:43-49.
19. Hyytiä P, Ingman K, Soini SL, Laitinen JT, and Korpi ER (1999) Effects of continuous opioid receptor blockade on alcohol intake and up-regulation of opioid receptor subtype signalling in a genetic model of high alcohol drinking. Naunyn Schmiedebergs Arch Pharmacol 360:391-401.
20. Ide S, Kobayashi H, Tanaka K, Ujike H, Sekine Y, Ozaki N, Inada T, Harano M, Komiyama T, Yamada M, et al. (2004) Gene polymorphisms of the mu opioid receptor in methamphetamine abusers. Ann N Y Acad Sci 1025:316-324.
21. Kas MJ, van den Bos R, Baars AM, Lubbers M, Lesscher HM, Hillebrand JJ, Schuller AG, Pintar JE, and Spruijt BM (2004) Mu-opioid receptor knockout mice show diminished food-anticipatory activity. Eur J Neurosci 20:1624-1632.
22. Kieffer BL and Gaveriaux-Ruff C (2002) Exploring the opioid system by gene knockout. Prog Neurobiol 66:285-306.
23. Li T, Jinsmaa Y, Nedachi M, Miyazaki A, Tsuda Y, Ambo A, Sasaki Y, Bryant SD, Marczak E, Li Q, et al. (2007) Transformation of mu-opioid receptor agonists into biologically potent mu-opioid receptor antagonists. Bioorg Med Chem 15:1237-1251.
24. Milligan G, MacEwan DJ, Mercouris M, and Mullaney I (1997) Inverse agonism at adrenergic and opioid receptors: studies with wild type and constitutively active mutant receptors. Receptors Channels 5:209-213.
25. Raehal KM, Lowery JJ, Bhamidipati CM, Paolino RM, Blair JR, Wang D, Sadee W, and Bilsky EJ (2005) In vivo characterization of 6β-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice. J Pharmacol Exp Ther 313:1150-1162.
26. Sadée W, Wang D, and Bilsky EJ (2005) Basal opioid receptor activity, neutral antagonists, and therapeutic opportunities. Life Sci 76:1427-1437.
27. Shoblock JR and Maidment NT (2006) Constitutively active mu opioid receptors mediate the enhanced conditioned aversive effect of naloxone in morphine-dependent mice. Neuropsychopharmacology 31:171-177.
28. Srisurapanont M and Jarusuraisin N (2005) Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 8:267-280.
29. Suzuki T and Misawa M (1997) Opioid receptor types and dependence. Nippon Yakurigaku Zasshi 109:165-174.
30. Thibault C, Hassan S, and Miles MF (2005) Using in vitro models for expression profiling studies on ethanol and drugs of abuse. Addict Biol 10:53-62.
31. Tryoen-Toth P, Decaillot FM, Filliol D, Befort K, Lazarus LH, Schiller PW, Schmidhammer H, and Kieffer BL (2005) Inverse agonism and neutral antagonism at wild-type and constitutively active mutant delta opioid receptors. J Pharmacol Exp Ther 313:410-421.
32. Walker EA and Sterious SN (2005) Opioid antagonists differ according to negative intrinsic efficacy in a mouse model of acute dependence. Br J Pharmacol 145:975-983.
33. Wang D, Raehal KM, Bilsky EJ, and Sadee W (2001) Inverse agonists and neutral antagonists at mu opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence. J Neurochem 77:1590-1600.
34. Wang D, Raehal KM, Lin ET, Lowery JJ, Kieffer BL, Bilsky EJ, and Sadee W (2004) Basal signaling activity of mu opioid receptor in mouse brain: role in narcotic dependence. J Pharmacol Exp Ther 308:512-520.
35. Wang Z, Bilsky EJ, Porreca F, and Sadee W (1994) Constitutive mu opioid receptor activation as a regulatory mechanism underlying narcotic tolerance and dependence. Life Sci 54:PL339-PL350.
36. Yano I and Takemori AE (1977) Inhibition by naloxone of tolerance and dependence in mice treated acutely and chronically with morphine. Res Commun Chem Pathol Pharmacol 16:721-734.
37. Zadina JE, Chang SL, Ge LJ, and Kastin AJ (1993) Mu-opiate receptor downregulation by morphine and up-regulation by naloxone in SH-SY5Y human neuroblastoma cells. J Pharmacol Exp Ther 265:254-262.
38. Zaki PA, Keith DE Jr, Thomas JB, Carroll FI, and Evans CJ (2001) Agonist-, antagonist-, and inverse agonist-regulated trafficking of the delta-opioid receptor correlates with, but does not require, G protein activation. J Pharmacol Exp Ther 298:1015-1020.
39. Zhang Y, Wang D, Johnson AD, Papp AC, and Sadee W (2005) Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J Biol Chem 280:32618-32624.